Enristomig

恩苏米单抗

Report date: 2026/03/27 20:01:50

Base Information

Drug NameEnristomig
Drug Alias NameINBRX-105-PDL1x41BB antibodyES101INBRX-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursSmall Cell Lung Carcinoma +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesInhibrx
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesInhibrx Biosciences IncElpiscience Biopharma LtdElpiscience (Suzhou) Biopharma Ltd
Active IndicationsN/A
Inactive IndicationsEsophageal adenocarcinomaSolid tumoursSmall Cell Lung Carcinoma +[12] 

Other Information

ATC CodeN/A
Related LinksN/A